Logo

Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a rare and severe disease that continues to progress over time.[1] Although there is no cure, recent advances in treatment strategies with increased therapeutic options have offered an improvement in prognosis and survival.[2],[3]

Prognosis
Treatment goal
Treatment of PAH
Treatment strategies

The prognosis of PAH depends on a number of modifiable clinical, functional, exercise, biochemical, echocardiographic and haemodynamic variables. Comprehensive assessment based on these parameters can determine prognosis by classifying patients as low-risk, intermediate-risk or high-risk for clinical worsening or death.[4] Patients across all risk categories have poor survival;[5] therefore, treatment strategies should target the improvement of long-term outcomes, with the ultimate goal of achieving a low-risk status.[4]

PAH-Explained-Treatment - Prognosis

Adapted from Hoeper et al. 2017[5]
PAH, pulmonary arterial hypertension

Diagnosis of PAH

Clinical guidelines set out the diagnostic pathway so patients can be referred and treated as quickly as possible.

Pathophysiology of PAH

While the exact cause of PAH is uncertain, a clearer picture of the underlying pathological mechanisms is emerging.

Get in touch with our team

Question or remark related PAH, the studies or our products? Click below to get in touch with a product specialist or medical science liaison.

Look at 3D clinical images

On this page you will find interactive 3D animations of the human anatomy and various syndromes. This allows you to zoom in on the anatomy, tissue structures, disease mechanisms and the course of the disease.

References

D’Alonzo GE et al. Ann Intern Med 1991; 115:343–349.
Benza RL et al. Chest 2012; 142:448–456.
Montani D et al. Orphanet J Rare Dis 2013; 8:97.
Galiè N et al. Eur Heart J 2016; 37:67–119.
Hoeper MM et al. Eur Respir J 2017; 50:1700740.
Boucly A et al. Eur Respir J 2017; 50:1700889.
Humbert M et al. Circulation 2014; 130:2189–2208.
Rosenkranz S, Dumitrescu D. Rev Esp Cardiol (Engl Ed) 2017; 70:901–904.
Lajoie A et al. Pulm Circ 2017; 7:312–325.
CP-192318 - November 2020